Pregnancy Exposure Registry for Tysabri®
Completed
Conditions studied: Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
In brief
The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.
Key facts
- Study ID
- NCT00472992
- Run by
- Biogen
- People needed
- 376
- Starts
- 2007-01-01
- Expected to finish
- 2012-07-01
- Last updated by the study team
- 2014-08-11
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- United BioSource Corporation — Morgantown, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.